Newsroom

SAN CARLOS, Kalifornien, USA--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, gab heute die vollständigen Ergebnisse der Phase-3-Studie HERIZON-GEA-01 bekannt. Die Studie untersuchte ZIIHERA® (Zanidatamab), einen HER2-gerichteten bispezifischen Antikörper, in Kombination mit einer Chemotherapie mit und ohne den PD-1-Inhibitor TEVIMBRA® (Tislelizumab) als Erstlinienbehandlung für ein HER2-positives (HER2+) lokal fortgeschr...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncología, anunció hoy los resultados completos del ensayo de Fase 3 HERIZON-GEA-01, que evaluó ZIIHERA® (zanidatamab), un anticuerpo biespecífico dirigido a HER2, en combinación con quimioterapia, con y sin el inhibidor de PD-1 TEVIMBRA® (tislelizumab), como tratamiento de primera línea para adenocarcinoma gástrico y esofágico HER2 positivo (HER2+) localmente avanzado o meta...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), azienda oncologica globale, oggi ha annunciato i risultati completi dello studio di fase 3 HERIZON-GEA-01 volto a valutare ZIIHERA® (zanidatamab), un anticorpo bispecifico mirato a HER2, in combinazione con chemioterapia, con e senza l'inibitore di PD-1 TEVIMBRA® (tislelizumab), come trattamento di prima linea nell'adenocarcinoma gastroesofageo (GEA) localmente avanzato o metastatico con espressio...

LIVONIA, Mich.--(BUSINESS WIRE)--Trinity Health today announced that it delivered $2.9 billion in programs and services during fiscal year 2025, reaffirming its commitment to patients and communities despite significant pressures facing the health care industry. Investments made across Trinity Health’s 25-state footprint include covering $310 million in care costs helping nearly 450,000 patients receive necessary routine and emergency care; completing more than 1 million screenings to identify...

LYON, France--(BUSINESS WIRE)--  Brenus Pharma annonce une tolérance favorable et des signaux cliniques positifs dans les premiers résultats préliminaires de son étude de première administration chez l'homme évaluant le STC-1010 chez des patients atteints d'un cancer colorectal métastatique non résécable (MSS CRC) Brenus Pharma, une société de biotechnologie en phase clinique qui active le système immunitaire in vivo pour lutter contre les tumeurs solides, a annoncé la réussite des premiers niv...

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to OHS Issuer, LLC, Series 2026-1/2 (OHS 2026-1/2 or the Series 2026-1/2 Notes), a service contract securitization that is primarily collateralized by home service contracts. OHS 2026-1/2 represents OHS Issuer, LLC’s (the Issuer) first securitization. The transaction structure is a master trust, and as such, the indenture permits the issuance of additional classes and series of notes subject to certain conditions, including rating agen...

PENSACOLA, Fla.--(BUSINESS WIRE)--Ametris today reported significant momentum with the pharmaceutical industry, including partnerships with eight of the top ten companies....

PHOENIX--(BUSINESS WIRE)--Attorney Jeremy Poryes has joined Dorsey & Whitney LLP as Of Counsel in the Real Estate group in Phoenix, the law firm announced today. Jeremy focuses on complex real estate acquisition, disposition, leasing, and financing transactions. His practice includes representing REITs and other real estate investors in the acquisition and disposition of retail properties (everything from single-site transactions to large property portfolios) advising buyers and sellers of...

SALT LAKE CITY--(BUSINESS WIRE)--Peter Ott has returned to Dorsey & Whitney LLP as a Partner in the Finance & Restructuring group in Salt Lake City, the international law firm announced today. Peter comes back to Dorsey after practicing at Parsons Behle & Latimer, where he was an Of Counsel attorney, and at Kirkland & Ellis LLP, where he was a Partner after practicing at Dorsey. He received his J.D. from University of Virginia School of Law and his B.A. from University of Utah....

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to 69 classes of mortgage pass-through certificates from Sequoia Mortgage Trust 2026-INV1 (SEMT 2026-INV1). The transaction consists of 1,191 investment property mortgages with an aggregate principal balance of $569.9 million as of the January 1, 2026 cut-off date. The collateral is characterized by a weighted average (WA) original credit score of 772 and moderate borrower equity, with a WA original LTV of 70.4% and WA original CLTV of...